Antidiabetic agents and cardiovascular outcomes in patients with heart diseases

References

• Center for Disease Control and Prevention: Diabetes National Data. Available at: http://www.cdc.gov/diabetes/data/national.html [Last accessed 29 June 2016]
   Google Scholar
• UK Prospective Diabetes Study Group. Intensive blood glucose control with sulfonylureas or insulin compared to conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes. (UKPDS 34). Lancet 1998;352:854-65
   PubMed Web of Science ®Google Scholar
• Gaster B, Hirsch IB. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med 1998;158:134-50
   PubMed Web of Science ®Google Scholar
• Vijan S, Hofer TP, Hayward RA. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med 1997;127:788-95
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;3342:381-9
   Google Scholar
• Pitale SU, Abraira C, Emanuele NV, et al. Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care 2000;23:1216-20
   Web of Science ®Google Scholar
• Stettler C, Allermann S, Juni P, et al. Glycemic control and macrovascular disease in type 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006;152:27-38
   PubMed Web of Science ®Google Scholar
• Dorman JS, LaPorte RE, Kuller LH, et al. The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study: mortality results. Diabetes 1984;33:271-6
   PubMed Web of Science ®Google Scholar
• Lehto S, Ronnemaa T, Pyorala K, Laakso M. Poor glycemic control predicts coronary heart disease events in patients with type 1 diabetes without nephropathy. Arterioscler Thromb Vasc Biol 1999;19:1014-19
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP et al.; for The Action to Control Glucose Lowering in Type 2 Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
   PubMed Web of Science ®Google Scholar
• The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory-Information/Guidances/ucm071627.pdf [Last accessed 29 June 2016]
   Google Scholar
• European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. May 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf [Last accessed 29 June 2016]
   Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247-57
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. M Engl J Med 2016;375:311-22
   PubMed Web of Science ®Google Scholar
• Marso SP. Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-1844
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28
   PubMed Web of Science ®Google Scholar
• Sirica BM, Bhatt DL, Braunwald E, et al.; for the SAVOR-TIMI 53 steering committee and investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al.; for the EXAMINE investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al.; for the TECOS study group. Effect of sitagliptin on cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2015:373:232-42
   PubMed Web of Science ®Google Scholar
• Goldner MG, Knatterud GL, Prout TE. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. JAMA 1971;218:1400-10
   PubMed Web of Science ®Google Scholar
• The ORIGIN trial investigators. Basal insulin and cardiovascular and other outcomes in dysglycemic. N Engl J Med 2012;367:319-28
   PubMed Web of Science ®Google Scholar
• Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007;147:578-81
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H, et al.; RECORD Study Group. Rosiglitazone evaluated for cardiac outcomes – an interim analysis. N Engl J Med 2007;357:28-38
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJA, et al.; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005;366:1279-89
   PubMed Web of Science ®Google Scholar
• Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized clinical trials. Lancet 2007;370:1129-36
   PubMed Web of Science ®Google Scholar
• Lipscombe LL, Gomes T, Levesque LE, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007;298:2634-43
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Hafley G, Dickerson S, et al. Results of a re-evaluation of cardiovascular outcomes in the RECORD trial. Am Heart J 2013;166:240-9
   PubMed Web of Science ®Google Scholar
• Gilbert RE, Krum H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet 2015;385:2107-2117
   PubMed Web of Science ®Google Scholar
• Kernan WN, Viscoli CM, Furie KL, et al.; for the IRIS investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016;374:1321-31
   PubMed Web of Science ®Google Scholar
• Nesto RW, Bell D, Bonow RO et al.; for the American Heart Association; American Diabetes Association. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and the American Diabetes Association. Circulation 2003;108:2941-8
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016;37:2129-200
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Diabetes medications containing saxagliptin and alogliptin: drug safety communication – risk of heart failure. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm486096.htm [Last accessed 5 April 2016]
   Google Scholar
• Zhong J, Maiseyeu A, Davis SN, Rajagopalan S. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ Res 2015;116:1491-504
   PubMed Web of Science ®Google Scholar
• Raschi E, Poluzzi E, Koci A, et al. Dipeptidyl peptidase-4 inhibitors and heart failure: analysis of spontaneous reports submitted to the FDA adverse event reporting system. Nutr Metab Cardiovasc Dis 2016;26:380-6
   PubMed Web of Science ®Google Scholar
• Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetes patients. J Clin Endocrinol Metab 2003;88:531-7
   PubMed Web of Science ®Google Scholar
• Ye Y, Perez-Polo JR, Aguilar D, Birnbaum Y. The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury. Basic Res Cardiol 2011;106:925-52
   PubMed Web of Science ®Google Scholar
• Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J 2015;36:2288-96
   PubMed Web of Science ®Google Scholar
• American Diabetic Association. Pharmacologic approaches to glycemic treatment. Diabetes Care 2017;40(Suppl 1):S64-S74
   Web of Science ®Google Scholar
• Jardiance Prescribing Information. Available at: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf [Last accessed 11 January 2017]
   Google Scholar